Premium
Cerebrospinal fluid choline levels are decreased in Parkinson's disease
Author(s) -
Manyam Bala V.,
Giacobini Ezio,
Colliver Jerry A.
Publication year - 1990
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410270616
Subject(s) - carbidopa , cerebrospinal fluid , levodopa , choline , medicine , parkinson's disease , acetylcholinesterase , amantadine , endocrinology , central nervous system disease , gastroenterology , chemistry , pharmacology , disease , biochemistry , enzyme
Abstract We examined acetylcholinesterase (AChE) activity and choline levels in cerebrospinal fluid (CSF) in 16 patients with idiopathic Parkinson's disease and 9 control subjects of corresponding age: 8 were untreated Parkinson's patients; 4 were treated with carbidopa‐levodopa (100/1,000 mg/day) for 20 ± 3 months; and 4 were treated with carbidopa‐levodopa (110/1,100 mg/day) for 28 ± 18 months plus amantadine (220 mg/day) for 16 ± 8 months. CSF choline levels (nmol/ml) were 2.97 ± 0.79 (control subjects); 1.31 ± 0.29 (untreated patients); 1.00 ± 0.29 (carbidopa‐levodopa treated); and 1.26 ± 0.19 (carbidopa‐levodopa/amantadine treated). Choline levels were significantly lower in untreated and treated patients compared to control subjects ( p = 0.0001). AChE activity did not differ in Parkinson's disease patients as compared to control subjects. The reduced level of choline in CSF may reflect a deficit in choline transport into the brain or a decrease of choline‐phospholipid output from the brain.